Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
Abbott Laboratories ABT
News
Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm
Abbott to Carve Out Nutrition Business Into Independent Company — 3rd Update
Abbott to Carve Out Nutrition Business Into Independent Company — 2nd Update
Abbott Labs to Carve Out Nutrition Business Into Independent Company — Update
Abbott Posts Lower 3Q Profit, Despite Higher Sales
Abbott to Carve Out Nutrition Business Into Independent Company
Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company
Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
Abbott hosts conference call for third-quarter earnings
Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio
This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval
Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health
Abbott declares 411th consecutive quarterly dividend
Abbott to Pay $385 Million to Resolve Baby Formula Contamination Claims
Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall
Abbott Receives FDA Approval for Device to Treat Abnormal Heart Rhythm
United States